Leukemia | Topics

Avapritinib Earns FDA Approval For Advanced Systemic Mastocytosis, Including Mast Cell Leukemia
June 16, 2021

Avapritinib is now fully approved to treated advanced systemic mastocytosis, according to phase 1 and phase 2 clinical trial data.

Vemurafenib Plus Rituximab Produced Durable Responses in Relapsed or Refractory Hairy-Cell Leukemia
May 28, 2021

A phase 2 trial evaluated the combination of vemurafenib plus rituximab, which produced a complete response in 87% of the evaluable patients with hairy-cell leukemia.

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia
February 24, 2021

A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.